Table 3.

Summary of treatment emergent adverse events

XG-102 Dose	Placebo	10 μg/kg	40 μg/kg	80 μg/kg
Number of subjects (%) with adverse events [number of adverse events]
Number of subjects treated	6	6	6	6
All treatment emergent adverse events
Mild	1 (16.7%) [2]	2 (33.3%) [2]	4 (66.7%) [4]	2 (33.3%) [3]
Moderate	1 (16.7%) [1]	1 (16.7%) [3]	1 (16.7%) [1]	0
Severe	0	0	0	0
Total	2 (33.3%) [3]	3 (50.0%) [5]	5 (83.3%) [5]	2 (33.3%) [3]
Possibly, probably, or definitely related adverse events
Mild	1 (16.7%) [1]	0	1 (16.7%) [1]	1 (16.7%) [1]
Moderate	1 (16.7%) [1]	0	1 (16.7%) [1]	0
Severe	0	0	0	0
Total	2 (33.3%) [2]	0	2 (33.3%) [2]	1 (16.7%) [1]
Subjects discontinued due to adverse events
Total	0	0	0	0
Subjects with serious adverse events
Total	0	0	0	0